Home » Stocks » NeuroMetrix

NeuroMetrix, Inc. (NURO)

Stock Price: $2.25 USD 0.10 (4.65%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $2.30 +0.05 (2.22%) Aug 7, 7:59 PM

Stock Price Chart

Key Info

Market Cap 8.52M
Revenue (ttm) 7.33M
Net Income (ttm) -3.97M
Shares Out 3.78M
EPS (ttm) -2.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $2.25
Previous Close $2.15
Change ($) 0.10
Change (%) 4.65%
Day's Open 2.12
Day's Range 2.12 - 2.27
Day's Volume 733,939
52-Week Range 0.81 - 6.20

More Stats

Market Cap 8.52M
Enterprise Value 4.37M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 3.78M
Float 3.75M
EPS (basic) -2.93
EPS (diluted) -2.39
FCF / Share -1.34
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 188,237
Short Ratio 0.41
Short % of Float 9.88%
Beta 2.52
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.16
PB Ratio 1.41
Revenue 7.33M
Operating Income -4.58M
Net Income -3.97M
Free Cash Flow -3.67M
Net Cash 4.14M
Net Cash / Share 1.09
Gross Margin 56.52%
Operating Margin -62.54%
Profit Margin -54.20%
FCF Margin -50.11%
ROA -29.33%
ROE -76.76%
ROIC -193.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$50.00*
Low
50.0
Current: $2.25
High
50.0
Target: 50.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue9.2716.0917.0912.037.305.515.287.5810.4013.90
Revenue Growth-42.37%-5.86%42.11%64.76%32.42%4.43%-30.32%-27.14%-25.2%-
Gross Profit2.257.386.864.913.352.943.083.995.676.85
Operating Income-11.53-12.29-13.08-15.21-13.28-8.77-7.36-10.02-10.00-17.31
Net Income-3.770.02-12.86-14.91-9.19-7.77-8.02-10.01-9.98-16.89
Shares Outstanding0.980.740.170.060.030.020.010.01--
Earnings Per Share-3.900.02-115.98-582.10-620.00-492.00-982.40-1,670.40-4,969.60-8,451.20
Operating Cash Flow-3.622.86-12.65-15.08-13.10-7.68-6.55-9.18-6.78-13.31
Capital Expenditures-0.05-0.14-0.16-0.10-0.59-0.23-0.09-0.11-0.11-0.31
Free Cash Flow-3.672.72-12.82-15.18-13.69-7.91-6.64-9.28-6.89-13.61
Cash & Equivalents3.136.784.043.9512.469.229.208.7010.5217.39
Total Debt1.511.88-----0.020.040.06
Net Cash / Debt1.624.904.043.9512.469.229.208.6810.4817.34
Assets6.8913.999.608.2816.1011.4010.8010.8814.2223.07
Liabilities4.367.894.583.323.548.023.602.083.132.87
Book Value2.536.105.024.9612.563.397.198.8011.0920.20
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name NeuroMetrix, Inc.
Country United States
Employees 23
CEO Shai N. Gozani

Stock Information

Ticker Symbol NURO
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: NURO

Description

NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.